Skip to content


  • Erratum
  • Open Access

Erratum to: Looking forward to new targeted treatments for chronic spontaneous urticaria

Clinical and Translational Allergy20177:11

  • Received: 13 March 2017
  • Accepted: 13 March 2017
  • Published:

The original article was published in Clinical and Translational Allergy 2017 7:1

Erratum to: Clin Transl Allergy (2017) 7:1 DOI 10.1186/s13601-016-0139-2

Information from the manufacturer of the topical intervention in the GSK2646264 trial outlined in this review [1] indicates that the half-life of the product has not been established with certainty on the available data.



Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Dermatology, Okmeydanı Training and Research Hospital, Istanbul, Turkey
Department of Dermatology and Allergy, Charité – Universitäts medizin, Berlin, Germany
St John’s Institute of Dermatology, Guy’s Hospital, London, UK


  1. Kocatürk E, Maurer M, Metz M, Grattan C. Looking forward to new targeted treatments for chronic spontaneous urticaria. Clin Transl Allergy. 2017;7:1.View ArticlePubMedPubMed CentralGoogle Scholar


© The Author(s) 2017